Mercator MedSystems touts data for Bullfrog microinfusion device

Mercator MedSystems touted data today from its Dance clinical trial evaluating the company’s Bullfrog micro-infusion device as a delivery system for a generic anti-inflammatory steroid, dexamethasome. Mercator’s results were presented at the International Symposium on Endovascular Therapy and Leipzig Interventional Course.

The steroid was delivered to tissues around femoropopliteal arteries after patients underwent endovascular intervention to forcibly open obstructions, the Emeryville, Calif.-based company said.

Get the full story at our sister site, Drug Delivery Business News.

The post Mercator MedSystems touts data for Bullfrog microinfusion device appeared first on MassDevice.

from MassDevice http://ift.tt/2lrY6rO